FAKTOR-OPTIONSSCHEIN - GENMAB | Real-time Boerse Frankfurt Warrants 20:50:55 25/06/2024 BST | ||
| 11.25 EUR | +0.45% |
|
| Current month | +15.15% | ||
| 1 month | +11.61% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 25/06/24 | 11.25 | +0.45% |
| 24/06/24 | 11.2 | -0.44% |
| 21/06/24 | 11.25 | -1.06% |
| 20/06/24 | 11.37 | -4.45% |
| 19/06/24 | 11.9 | +6.34% |
Real-time Boerse Frankfurt Warrants
Last update June 25, 2024 at 08:50 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
Société Générale
|
| WKN | SW9NAT |
| ISIN | DE000SW9NAT5 |
| Date issued | 29/04/2024 |
| Strike | 1,916 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.13 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.02 € |
|---|---|
| Lowest since issue | 8.76 € |
| Spread | 0.22 € |
| Spread % | 1.92% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,799
DKK
Average target price
2,464
DKK
Spread / Average Target
+36.96%
- Stock Market
- Certificates
- Certificat
